MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase 1
Recruiting
Conditions
Hematologic Neoplasms
Interventions
First Posted Date
2022-04-14
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
430
Registration Number
NCT05327023
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Phase 1
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2022-04-12
Last Posted Date
2022-04-12
Lead Sponsor
The Affiliated Hospital of Xuzhou Medical University
Target Recruit Count
15
Registration Number
NCT05323201
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Phase 2
Recruiting
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
First Posted Date
2022-04-12
Last Posted Date
2022-04-19
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
25
Registration Number
NCT05322733
Locations
🇨🇳

Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Phase 1
Withdrawn
Conditions
Recurrent Acute Myeloid Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Refractory T Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent T Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Interventions
First Posted Date
2022-04-11
Last Posted Date
2023-09-01
Lead Sponsor
Children's Oncology Group
Registration Number
NCT05320380

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Phase 1
Recruiting
Conditions
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse
Interventions
First Posted Date
2022-04-07
Last Posted Date
2024-11-26
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
40
Registration Number
NCT05317403
Locations
🇺🇸

Children's Wisconsin, Milwaukee, Wisconsin, United States

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

First Posted Date
2022-03-31
Last Posted Date
2022-07-01
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
64
Registration Number
NCT05303727
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

First Posted Date
2022-02-25
Last Posted Date
2024-11-14
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
750
Registration Number
NCT05257083
Locations
🇺🇸

University of Arkansas, Little Rock, Arkansas, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

UC San Diego Health Moores Cancer Center, San Diego, California, United States

and more 122 locations

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1
Terminated
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Interventions
First Posted Date
2022-02-17
Last Posted Date
2023-07-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
5
Registration Number
NCT05244070
Locations
🇺🇸

Local Institution - 0026, Hackensack, New Jersey, United States

🇺🇸

Local Institution - 0007, Boston, Massachusetts, United States

🇺🇸

Local Institution - 0005, Birmingham, Alabama, United States

and more 5 locations

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Phase 1
Recruiting
Conditions
Platinum-Resistant Ovarian Carcinoma
Interventions
Biological: Chimeric Antigen Receptor T-cells
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2022-02-04
Last Posted Date
2024-05-23
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
33
Registration Number
NCT05225363
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath